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Chamaka Kalutota, Dr. Emanuel Rubin
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Philadelphia
In recent years, liquid biopsy has emerged as a potential alternative/adjunct to standard
tissue biopsy in the diagnosis of malignancies. Current use of this technique, which tracks
distinctive molecules released from neoplastic cells including circulating tumor cells
(CTCs), exosomes, circulating tumor DNA (ctDNA), cell-free DNA (cfDNA) and
miRNA, has generally been limited to determining therapies in lung cancer based on
detectable mutations (EFGR, EML4-ALK). However, recent studies have demonstrated
the possibility for using these molecules as more efficient prognostic and diagnostic
biomarkers in breast, colon, rectum, lung, liver, and pancreatic cancer. Due to the need
for standardization in sampled material (serum, plasma, urine), the types of molecules
being investigated, and the techniques used to evaluate these molecules (ARMS/Scorpion
assay, PNA probing, BEAM analysis, digital PCR, etc.), the idea of using liquid biopsy
as a stand-alone method of diagnosis and prognosis requires further examination and
collaboration among practitioners. Yet, its low invasiveness compared to standard
methods of diagnosis as well as its capability of lending practitioners a more enhanced
ability to track the development of a malignancy over time, particularly in patients who
cannot tolerate repeated tissue biopsies, and to identify mutational heterogeneity in
malignancies merits continued interest in its potential.
	
  

